425: BioNTech Q3 Sees Revenue Boost from BMS Deal, Net Loss Persists

BioNTech's third-quarter revenue surged 22% driven by a significant out-licensing deal with Bristol-Myers Squibb, despite a decline in COVID-19 vaccine sales and a confirmed full-year net loss outlook.

Summary

• Total revenues for the three months ended September 30, 2025, increased by 22% to €1,518.9 million, up from €1,244.8 million in the prior-year period.
• Nine-month revenues increased by 26% to €1,962.5 million, compared to €1,561.1 million for the same period in 2024.
• COVID-19 vaccine revenues decreased by 23% in Q3 2025 to €853.3 million and by 13% for the nine months to €1,139.6 million, primarily due to lower dose volumes.
• Revenues from out-licensing surged to €613.0 million in both the three and nine months ended September 30, 2025, from nil in the prior periods, driven by the global strategic partnership with Bristol-Myers Squibb (BMS).
• The company reported a net loss of €28.7 million for Q3 2025, a significant decrease from a net profit of €198.1 million in Q3 2024.
• The nine-month net loss decreased by 10% to €831.1 million in 2025, compared to a net loss of €924.8 million in 2024.
• Operating loss for Q3 2025 was €46.9 million, a shift from an operating profit of €10.5 million in Q3 2024.
• Nine-month operating loss decreased by 26% to €1,082.1 million in 2025, from €1,462.9 million in 2024.
• Research and development expenses increased by 3% in Q3 2025 to €564.8 million, mainly due to late-stage trials for immuno-oncology and antibody-drug conjugate programs, partly offset by cost savings and a one-time impairment of BNT323/DB-1303.
• General and administrative expenses decreased by 8% in Q3 2025 to €121.2 million, driven by a reduction in external services.
• Other operating expenses increased significantly due to a €678.5 million settlement with GSK/CureVac related to patent litigation.
• Cash and cash equivalents stood at €10,092.9 million as of September 30, 2025, an increase from €9,761.9 million at December 31, 2024.
• The company confirmed its outlook for a net loss in the financial year 2025, with expected revenues between €2.6 billion and €2.8 billion.
• The public exchange offer for all outstanding shares of CureVac N.V. commenced on October 22, 2025, with an implied aggregate equity value of approximately $1.25 billion, expiring on December 3, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While BioNTech shows strong strategic execution with the BMS partnership and Biotheus acquisition, leading to significant revenue growth from out-licensing, and a reduction in the nine-month net loss, the shift to a net loss in Q3 2025 and the confirmed full-year net loss outlook, coupled with declining COVID-19 vaccine revenues and substantial legal settlement expenses, balance out the positives. The ongoing legal challenges and pipeline prioritization costs also contribute to a cautious outlook, despite promising oncology pipeline developments.

Positives

• Total revenues increased by 22% in Q3 2025 and 26% for the nine months ended September 30, 2025, primarily driven by a new out-licensing agreement.
• Secured a global strategic partnership with Bristol-Myers Squibb (BMS) for pumitamig (BNT327/BMS986545), including a $1.5 billion upfront payment and eligibility for up to $9.6 billion in future payments.
• Operating loss for the nine months ended September 30, 2025, decreased by 26% compared to the prior-year period, indicating improved operational efficiency or reduced negative impacts.
• Net cash flows from operating activities significantly improved in Q3 2025, reaching €780.7 million compared to a negative €638.9 million in Q3 2024.
• Cash and cash equivalents increased to over €10 billion as of September 30, 2025, demonstrating strong liquidity.
• Progress in the oncology pipeline with the initiation of a Phase 3 trial for BNT323/DB-1303 in endometrial cancer and planned global Phase 2/3 trials for BNT327 in metastatic CRC and gastric cancer.
• Positive topline results from the Phase 3 trial for the LP.8.1-adapted monovalent COVID-19 vaccine, showing robust neutralizing antibodies and a consistent safety profile.
• China's NMPA granted Breakthrough Therapy Designation for gotistobart (BNT313/GEN1047) for squamous non-small cell lung cancer.

Negatives

• Net profit shifted to a loss of €28.7 million in Q3 2025 from a profit of €198.1 million in Q3 2024.
• COVID-19 vaccine revenues continued to decline, decreasing by 23% in Q3 2025 and 13% for the nine months ended September 30, 2025.
• Operating profit shifted to a loss of €46.9 million in Q3 2025 from a profit of €10.5 million in Q3 2024.
• Significant other operating expenses incurred due to a €678.5 million settlement related to patent litigation with GSK/CureVac.
• Finance result decreased by 52% in Q3 2025 and 47% for the nine months, mainly due to lower interest income and negative foreign exchange differences.
• One-time impairment loss of €85.4 million recognized for product candidate BNT323/DB-1303 due to a revision of commercial forecast assumptions.
• Development program for BNT312/GEN1042 in combination with pembrolizumab and chemotherapy discontinued due to strategic evaluation.

Risks

• Demand for COVID-19 vaccines is expected to continue to decrease, impacting revenues which are currently heavily dependent on these sales.
• Changes in local, national, and state government policy preferences, including vaccine recommendations and evolving public sentiment, could affect demand for COVID-19 vaccines or mRNA therapeutics.
• Inability to increase marketing and sales capabilities independently or through third parties may hinder effective commercialization of product candidates.
• Government policies, including those related to manufacturing, export controls, tariffs, and negative public perception regarding vaccines and mRNA-based therapeutics, could severely impact manufacturing and sales.
• Long-term sustainable profitability is difficult to achieve and maintain, highly dependent on factors like new virus variants, regional policy changes, and public health measures.
• Ability to use net operating losses (NOLs) and research and development credits to offset future taxable income may be subject to limitations and uncertainty, as the company anticipates incurring losses for the majority of group entities in the future.
• Failure to appropriately account for complex terms in collaboration and licensing agreements could require restatement of financial statements, materially adversely affecting financial condition and results of operations.
• Business is dependent on the successful development, regulatory approval, and commercialization of product candidates, with significant harm if approvals are not obtained or commercialization is ineffective.
• Ongoing intellectual property disputes and contractual disputes with various parties (e.g., CureVac, Moderna, Arbutus, Genevant, GlaxoSmithKline, Promosome) pose contingent liabilities with uncertain outcomes and potential for material adverse effects.
• Product-related disputes and shareholder claims (e.g., Ladewig Proceedings) represent contingent liabilities, with the potential for judgments or settlements that could materially impact financial results.

Future Outlook

BioNTech confirms its expectation of a net loss for the full financial year 2025. Revenues are projected to be between €2.6 billion and €2.8 billion. Research and development expenses are anticipated to be between €2.0 billion and €2.2 billion, with sales, general, and administrative expenses between €550.0 million and €650.0 million. Operating investments in property, plant, and equipment and intangible assets are expected to be between €200.0 million and €250.0 million, excluding any potential investments from CureVac post-acquisition. The company has launched its variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season and aims to make significant progress in its oncology pipeline, particularly late-stage development, while continuing COVID-19 vaccine development, including combination with flu protection.

Management Comments

• The company does not expect to report a positive net income figure for the 2025 financial year.
• Based on the current development of the year 2025, the company confirms that it does not expect to report a positive net profit / (loss) figure for the year 2025.
• We believe that any such request for amendment (in Ladewig Proceedings) would be meritless and untimely. However, should plaintiffs obtain leave to amend their pleading, we believe that we have strong defenses against the allegations claimed and intend to vigorously defend ourselves in the lawsuit mentioned above.

Industry Context

BioNTech is navigating a significant transition from its peak COVID-19 vaccine revenues towards a diversified pipeline, primarily in oncology. The decline in COVID-19 vaccine sales reflects broader market trends as the pandemic shifts to an endemic phase, reducing demand for initial mass vaccination campaigns. The strategic partnership with BMS and the acquisition of Biotheus underscore a strong commitment to expanding its oncology portfolio, particularly in bispecific antibodies and ADCs, which are high-growth areas in cancer therapy. Increased R&D spending in non-COVID-19 areas aligns with industry efforts to innovate beyond the pandemic. The numerous patent litigations highlight the intense competitive and intellectual property landscape within the mRNA and broader biopharmaceutical sectors.

Comparison to Industry Standards

• NA

Management Changes

Legal Proceedings

• Alnylam Proceedings: Lawsuits alleging infringement of patents by Comirnaty were settled, with a final judgment of noninfringement entered on July 30, 2025, and a settlement agreement and covenant not to sue entered on August 29, 2025.
• CureVac Proceedings (Germany): EP122 was nullified by the Federal Patent Court on December 19, 2023, with an appeal pending. DE961 and DE974 were cancelled by the German Patent and Trademark Office on June 26, 2024, with appeals pending. EP668 and EP755 were upheld in amended form by the EPO Opposition Division, with BioNTech appealing both decisions; infringement hearings are postponed to mid-January 2026, and GSK has filed requests to intervene in both.
• CureVac Proceedings (United States): Patent litigation was resolved through a settlement agreement entered on August 7, 2025, which also set a framework for resolving ex-US patent litigation.
• Moderna Proceedings (Germany): The EPO Opposition Division revoked EP565 on November 7, 2023 (Moderna appealed, preliminary opinion suggests likely invalidity). The Düsseldorf Regional Court found infringement of EP949 on March 5, 2025 (BioNTech and Pfizer appealed, EPO appeal pending).
• Moderna Proceedings (United Kingdom): The UK High Court found EP565 invalid and EP949 valid and infringed. The UK Appeals Court denied Moderna's appeal for EP565, making it finally revoked. The UK Court of Appeal upheld EP949's validity (BioNTech applied for permission to appeal to the UK Supreme Court).
• Moderna Proceedings (United States): District Court litigation stayed pending Inter Partes Review (IPR). The PTAB found challenged claims of U.S. Patent Nos. 10,933,127 and 10,702,600 unpatentable/invalid on March 5, 2025 (Moderna appealed).
• Moderna Proceedings (Netherlands, Ireland, Belgium): Ongoing, with most proceedings stayed pending outcomes of EPO opposition proceedings.
• Arbutus and Genevant Proceedings (United States): Lawsuit alleging infringement of patents by Comirnaty is pending.
• GlaxoSmithKline Proceedings (United States, Ireland, Unified Patent Court, United Kingdom): Multiple new lawsuits filed by GSK in 2024/2025 alleging Comirnaty's infringement of various patents are pending. BioNTech believes it has strong defenses.
• Promosome Proceedings (Unified Patent Court): Lawsuit filed in January 2025 alleging Comirnaty infringes EP 2 401 365 is pending, with an oral hearing scheduled for May 2026.
• Ladewig Proceedings (Securities Class Action): The U.S. District Court dismissed the operative complaint in its entirety on September 30, 2025. Plaintiffs did not file an appeal by the October 30, 2025, deadline, nor have they moved to amend their pleading.

Related Party Transactions

• ATHOS KG and entities controlled by them provide rental and property management activities and sell property, plant, and equipment to BioNTech. The total amount of transactions had no significant impact on the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025.
• Members of the Management Board and the Supervisory Board are related parties as key management personnel. The total amount of transactions with related parties had no significant impact on the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: The confirmed net loss outlook for 2025 and the shift to a net loss in Q3 2025 may negatively impact investor sentiment, despite strategic growth initiatives. The CureVac acquisition, if successful, will dilute existing BioNTech shareholders but could offer long-term strategic benefits.
• Employees: The acquisition of Biotheus added over 300 employees, expanding BioNTech's workforce. Pipeline prioritization costs and restructuring due to pipeline prioritization indicate potential impacts on employee-related obligations and roles.
• Customers: Continued development of COVID-19 vaccines and new oncology candidates aims to address unmet medical needs, benefiting patients. The narrower FDA approval for the LP.8.1-adapted COVID-19 vaccine may limit its reach to certain patient populations.
• Suppliers/Partners: The BMS partnership represents a significant collaboration, impacting development and manufacturing costs and future profit sharing. Ongoing relationships with CMOs are affected by obligations from onerous contracts due to redundant production capacities.
• Creditors: Strong cash and cash equivalents position of over €10 billion provides financial stability, but ongoing net losses and significant legal settlement expenses could be a concern if not managed effectively.

Next Steps

• Investors who have already agreed to purchase or subscribe for the Offer ADSs during the initial offer period have the right to withdraw their acceptances until November 14, 2025.
• The public exchange offer for CureVac N.V. shares will expire at 9:00 a.m. (New York City time) on December 3, 2025, unless extended or terminated earlier.
• BioNTech and DualityBio plan to file a biologics license application for BNT323/DB-1303 in second-line endometrial cancer in 2026, subject to regulatory feedback.
• Global Phase 2/3 clinical trials (ROSETTA CRC-203; NCT07221357) in patients with first-line MSS, MSI-L/pMMR metastatic CRC are planned.
• Global Phase 2/3 clinical trials (ROSETTA Gastric-204; NCT07221149) in patients with first-line metastatic gastric cancer are planned.
• Clinical trials are ongoing in collaboration with Pfizer to evaluate the safety, tolerability, and immunogenicity of the COVID-19 and influenza combination mRNA vaccine candidates.
• An oral hearing on CureVac's appeal of the nullification of EP122 is scheduled for July 2026.
• An oral hearing regarding the validity of CureVac's DE130 patent before the German Patent and Trademark Office is scheduled for December 8, 2025.
• An oral hearing for Moderna's appeal of the Opposition Division's revocation decision on EP565 is scheduled for January 27, 2026.
• An oral hearing for BioNTech's appeal of the EPO Opposition Division's decision on Moderna's EP949 patent is scheduled for September 2026.
• An oral hearing for Promosome's lawsuit against BioNTech and Pfizer in the UPC Munich Division is scheduled for May 2026.

Key Dates

Recommendation

BioNTech is in a transitional phase, marked by declining COVID-19 vaccine revenues but strong strategic moves into oncology through the BMS partnership and Biotheus acquisition. While the significant out-licensing revenue boosted Q3 results, the company still reported a net loss for the quarter and confirmed a full-year net loss for 2025. The substantial cash reserves provide a buffer for continued R&D investment in its promising oncology pipeline. However, the numerous ongoing patent litigations and the impairment charge on a product candidate introduce considerable uncertainty and financial risk. Given the mixed financial performance, the strategic pivot, and the legal overhang, a 'hold' recommendation is appropriate. Investors should monitor the progress of the oncology pipeline, the resolution of legal disputes, and the successful integration of the CureVac acquisition for clearer long-term direction.

Keywords

BioNTech, CureVac, SEC Filing, 425 Filing, Prospectus Supplement, Q3 2025 Earnings, Financial Results, COVID-19 Vaccine, mRNA Therapeutics, Oncology Pipeline, BMS Partnership, Biotheus Acquisition, Patent Litigation, Net Loss, Revenue Growth, R&D Expenses, Biotechnology, Pharmaceuticals, Merger & Acquisition